Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-16. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Doris Ludlam, died 27 June 2002. Bridget Bourke, died 22 July 2002. Irene Crooks, died 20 October 2002. Ethel Hall, died 11 December 2002. All of these victims had been killed in Norris's first year of working as a nurse. Hall was a mother of one and a grandmother of two. Ludlam was a mother of two, a grandmother and great-grandmother who had worked as a nursery school teacher and fostered children for the charity Barnardo's. Wilby was a vulnerable widow. Crooks died on her 79th birthday, unable to ever open her cards or presents. Hall's son Stuart expressed his relief at Norris's conviction, stating: "I think he needs to be kept inside". He added: "He has got the knowledge to kill people and to do it discreetly. That makes him a danger to society and he must be kept inside. We hope Colin Norris never leaves prison and can never harm anyone else again." After the verdict was announced, Leeds Teaching Hospitals NHS Trust apologised to the victims' families for Norris's "disturbing" crimes, subsequently describing him as an "extremely dangerous criminal". In 2009, the Nursing and Midwifery Council struck off Norris from the medical register, taking just five minutes to come to a decision on the matter. Norris was imprisoned at HM Prison Frankland.
Subacute combined degeneration is also a degeneration of the spinal cord, but instead vitamin B12 deficiency is the cause of the spinal degeneration. SCD also has the same high T2 signalling intensities in the posterior column as copper deficient patient in MRI imaging.
Bulk materials (>100 nm in size) are expected to have constant physical properties (such as thermal and electrical conductivity, stiffness, density, and viscosity) regardless of their size, for nanoparticles, however, this is different: the volume of the surface layer (a few atomic diameters-wide) becomes a significant fraction of the particle's volume; whereas that fraction is insignificant for particles with a diameter of one micrometer or more. In other words, the surface area/volume ratio impacts certain properties of the nanoparticles more prominently than in bulk particles.
== Image and legacy == Noriega's authoritarian rule of Panama has been described as a dictatorship, while Noriega himself has been referred to as a "strongman". A 2017 obituary from the BBC stated that Noriega "was an opportunist who used his close relationship with the United States to boost his own power in Panama and to cover up the illegal activities for which he was eventually convicted". A 2010 article in The Guardian referred to him as the best known dictator of his time, and as "Panama's answer to Libyan leader Colonel Muammar Gaddafi". Dinges writes that though Noriega's regime saw a number of murders and crimes, they were similar in scale to those that occurred at the same time under the authoritarian governments of Guatemala, Chile, Argentina, and El Salvador; these governments never saw the level of condemnation from the U.S. that Noriega's did. Others likened him to former Iraqi president Saddam Hussein. Like Saddam, Noriega enjoyed brief U.S. support until he turned into an enemy. After Noriega's death, an article in The Atlantic compared him to Castro and Augusto Pinochet, stating that while Castro had been the nemesis of the U.S., and Pinochet had been its ally, Noriega had managed to be both. It called Noriega the archetype of U.S. intervention in Latin America: "The lawless, vicious leader whom the U.S. cultivated and propped up despite clear and serious flaws." The author stated that although Panama was a freer democracy after Noriega's removal, it was still plagued by corruption and drug trafficking, while Daniel Ortega, whom the U.S.
Candelariella deppeanae is a species of lichen in the family Candelariaceae. Found in southwestern North America, it was formally described as a new species in 2007 by the Swedish lichenologist Martin Westberg. The type specimen was collected in the Chiricahua Mountains (Chiricahua National Monument, Arizona) at an elevation of 1,750 m (5,740 ft). Here, in an oak forest, it was found growing on a decorticated (barkless) part of alligator juniper (Juniperus deppeana). Most collections of the lichen are from the wood or trunks of this juniper plant; the species epithet deppeanae alludes to this close relationship. The lichen has a greenish-yellow to yellow, granular to areolate thallus. It has also been collected in Texas, and from Chihuahua, Baja California Norte and Baja California Sur. The lichen grows mainly on wood and decorticated trunks, but has also been less frequently recorded growing on bark. Secondary chemicals that have been detected in Candelariella deppeanae (using high-performance liquid chromatography) include calycin, pulvic acid lactone, vulpinic acid, and pulvinic acid.
Sources: en.wikipedia.org
Low Apgar scores, <5 at 5 minutes and 10 minutes. Floppiness, or unreactive to sights or sounds, or more tense and agitated. Low heart rate. Low blood pressure. Poor muscle tone and absent reflexes. Weak breathing, no breathing at all, or rapid breathing. Need for resuscitation after delivery. Weak cry. Bluish or pale skin color. Excessive acid in the blood. Seizures or abnormal movements. Problems feeding
1993/2924) Social Security (Contributions) Amendment (No. 7) Regulations 1993 (S.I. 1993/2925) Dundee Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2926) Falkirk and District Royal Infirmary National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2927) Hairmyres and Stonehouse Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2928) Law Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2929) Perth and Kinross Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2930) East and Midlothian National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2931) Royal Infirmary of Edinburgh National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2932) Western General Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2933) Dumfries and Galloway Acute and Maternity Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2934) Glasgow Community and Mental Health Services National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2935) Edinburgh Sick Children's National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2936) Fife Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2937) Edinburgh Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2938) Petroleum Revenue Tax (Nomination Scheme for Disposals and Appropriations) (Amendment) Regulations 1993 (S.I.
=== Lithium === Lithium which is used in the treatment of bipolar disorder was the first natural GSK-3 inhibitor discovered. It inhibits GSK-3 directly by competition with magnesium ions and indirectly by phosphorylation and auto-regulation of serine. Lithium has been found to have insulin-like effects on glucose metabolism, including stimulation of glycogen synthesis in fat cells, skin, and muscles, increasing glucose uptake, and activation of GS activity. In addition to inhibition of GSK-3, it also inhibits other enzymes involved in the regulation of glucose metabolisms, such as myo-inositol-1-monophosphatase and 1,6 bisphosphatase. Also, it has shown therapeutic benefit in Alzheimer's and other neurodegenerative diseases such as epileptic neurodegeneration.
In 1809, Karađorđe appealed to an alliance with the Habsburgs and Napoleon, with no success, even wrote personally to Napoleon seeking military assistance, and in 1810, dispatched an emissary to the French Empire. However, the French did not believe that the rebels had the military capacity to defeat the Ottomans or expulse them from the Balkans. In 1812, under pressure from Napoleon, Russia was forced to sign the Treaty of Bucharest, which restored peace with the Ottomans. One of the clauses of the treaty provided for the maintenance of Serbian autonomy, also, a truce was signed according to the Article 8 of the Treaty. Then, the Russians encouraged Karađorđe and his followers to negotiate directly with the Porte.
The group 11 metals (or coinage metals), copper, silver, and gold, are typically categorised as transition metals given they can form ions with incomplete d-shells. Physically, they have the relatively low melting points and high electronegativity values associated with post-transition metals. "The filled d subshell and free s electron of Cu, Ag, and Au contribute to their high electrical and thermal conductivity. Transition metals to the left of group 11 experience interactions between s electrons and the partially filled d subshell that lower electron mobility." Chemically, the group 11 metals behave like main-group metals in their +1 valence states, and are hence somewhat related to the alkali metals: this is one reason for their previously being labelled as "group IB", paralleling the alkali metals' "group IA". They are occasionally classified as post-transition metals. Their spectra are analogous to those of the alkali metals. Their monopositive ions are paramagnetic and contribute no colour to their salts, like those of the alkali metals. In Mendeleev's 1871 periodic table, copper, silver, and gold are listed twice, once under group VIII (with the iron triad and platinum group metals), and once under group IB. Group IB was nonetheless parenthesised to note that it was tentative. Mendeleev's main criterion for group assignment was the maximum oxidation state of an element: on that basis, the group 11 elements could not be classified in group IB, due to the existence of copper(II) and gold(III) compounds being known at that time.
Sources: en.wikipedia.org
A GFD involves removing all food and drink that contains wheat, rye, barley, and gluten derivatives. Coeliac disease symptoms can improve within days of adopting a GFD, and the diet improves quality of life, prevents further complications, and can normalise some effects of the disease such as stunted growth. The GFD can be difficult, requiring significant education and motivation. Additionally, the GFD diet may lead to nutritional deficiencies due to difficulties accessing nutritionally balanced gluten-free food. As such, a referral to a dietitian is recommended by treatment guidelines. A dietitian can help those with coeliac disease identify gluten-containing food and maintain a nutritionally balanced diet. The exact amount of gluten that may be tolerable for those with coeliac disease varies, with some people able to consume around 35 mg per day without damage to the intestines, while others can not tolerate more than 10 mg a day. Currently, international regulatory agencies require a product to contain less than 20 ppm (about 6 mg per day) of gluten to be labelled as gluten-free.
== Rise to prominence (1970–1976) == In 1971, Mahathir announced his plan to rejoin UMNO, stating he would make a formal statement at an appropriate time; that same year, he also met Prime Minister Abdul Razak Hussein during a visit to Morib. Mahathir rejoined UMNO on 7 March 1972. Recognizing his potential and sharp political acumen, Razak appointed Mahathir as a Senator for Kedah in 1973. Around the same time, Mahathir also became the chairman of Food Industries of Malaysia (FIMA) Sdn. Bhd. In January 1973, as chairman of the FIMA, Mahathir visited a government factory in Pekan Nanas. He faced peaceful protests from over 200 workers demanding better working conditions and wage improvements. After Mahathir spoke to the workers and promised to review their grievances, they dispersed peacefully. He remained chairman of FIMA until 1981, when he became prime minister and was succeeded by Basir Ismail. Mahathir rose quickly in the Abdul Razak government, returning to UMNO's Supreme Council in 1973. He returned to the House of Representatives in the 1974 election, winning the Kedah-based seat of Kubang Pasu unopposed. He was appointed to Cabinet in September 1974 as the Minister for Education. During his tenure, Mahathir rolled out a new school curriculum for both primary and secondary schools, designed to provide holistic education and cultivate well-rounded individuals. Around this time, he also ceased his private medical practice. In 1975, Mahathir ran for one of the three vice-presidencies of UMNO.
== Sources == The main source of atmospheric BaP is residential wood burning. It is also found in coal tar, in automobile exhaust fumes (especially from diesel engines), in all smoke resulting from the combustion of organic material (including cigarette smoke), and in charbroiled food. Data collected in 2024 by the European Environment Agency from all, except Portugal, EU-27 Member States as well as from Norway and Switzerland showed that the highest concentrations of BaP were found in eastern Europe and Italy, mainly associated with residential heating using coal, wood or derivatives. Methods of identifying BaP in foods have advanced over the years but difficulties remain in balancing speed with accuracy. Established methods include gas chromatography–mass spectrometry and high-performance liquid chromatography with fluorescence detection. A 2001 National Cancer Institute study found levels of BaP to be significantly higher in foods that were cooked well-done on the barbecue, particularly steaks, chicken with skin, and hamburgers: Cooked meat products have been shown to contain up to 4 ng/g of BaP, and up to 5.5 ng/g in fried chicken and 62.6 ng/g in overcooked charcoal barbecued beef. In 2008 the European Food Safety Authority stated that BaP was the only PAH that was regulated in food at the time. However, they stated it was not a suitable standalone indicator for the occurrence of PAHs in food and recommended using the sum of either four or eight PAHs as more suitable indicators for that matter.
genome size The total amount of DNA contained within one copy of a genome, typically measured by mass (in picograms or daltons) or by the total number of base pairs (in kilobases or megabases). For diploid organisms, genome size is often used interchangeably with C-value.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.